EGFR and non-small cell lung carcinoma: Nevertheless, to the best of our knowledge, this is the first study to demonstrate that antacid use adversely affected OS among patients with advanced-stage EGFR-mutant NSCLC who were treated using first-line EGFR-TKIs.